Rainbow Seed Fund Backs New STFC Spin Out MIRICO
Spin out from UK publicly-funded research develops novel laser spectroscopy for environmental, medical diagnosis and…read more
The Rainbow Seed Fund is a £24m early-stage venture capital fund building and growing technology companies stemming from the UK’s research base.
We help build companies from great science developed in: public laboratories, science and technology campuses and synthetic biology.
We hold investments in some of the UK’s most innovative companies, in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.
We’re prepared to invest early and help build a commercial proposition around a technology to attract additional investment needed to get to market.
The Fund’s investment criteria which must be met for us to invest are:
1. Projects and companies arise from world-class research carried out in our partner laboratories across the UK, including those at Rutherford Appleton Laboratory (STFC), Babraham Institute (BBSRC) and Porton Down (Dstl).
2. Companies are based at or relocating to our partners’ national science and innovation campuses in Harwell Oxford, Babraham Cambridge, Daresbury Warrington and Norwich.
3. UK Companies working in the field of synthetic biology: Synthetic biology is an exciting new discipline based on the design and engineering of biologically-based parts, novel devices and systems and the redesign of existing, natural biological systems.
A key part of our value in economic terms is in the pivotal early role we play in getting technology companies off the ground, often whilst they are still in the laboratory and before they are ready to spin out. Many of our companies might never have made it, if it had not been for our support and the technologies and services they offer would not have progressed beyond an interesting concept.
In recognition of these achievements, in November 2013 the Rainbow Seed Fund received an additional £10M investment to support the commercialisation of synthetic biology technologies.
This funding was in response to the Synthetic Biology Roadmap, which sets out plans to harness opportunities in the field of synthetic biology. Synthetic biology is one of the eight great technologies highlighted by the UK government as an area of wide-ranging significance and potential economic importance, and in which the UK’s research base is particularly strong.
More information on the Fund can be found at: www.rainbowseedfund.com
Current As At: 31st January 2016
Fund Amount £24m
4 Profitable Exits
Contego CEO Adrian Black is looking forward to working in the collaborative environment at Level39…read more
Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics, has announced the…read more